Retia Medical

Executive Summary

Retia Medical is a privately held U.S. medical device company specializing in cardiovascular monitoring. Founded in 2015 and based in Valhalla, New York, the company develops software-driven solutions that convert routine physiological signals (e.g., ECG, blood pressure) into actionable cardiac output data. Its flagship product, the Argos Cardiac Output Monitor, and the Argos Infinity enterprise platform aim to provide continuous, non-invasive hemodynamic monitoring for early detection of patient deterioration. The platform is designed for both bedside and hospital-wide use, potentially reducing adverse events such as sepsis, heart failure, and shock. Retia targets a significant unmet need in hospitals, where current cardiac output monitoring is often invasive, intermittent, or resource-intensive. The company’s approach leverages existing vital sign data, eliminating the need for specialized catheters or additional sensors, which could lower costs and improve adoption rates. With a focus on improving clinical outcomes and reducing hospital-acquired harms, Retia Medical is well-positioned in the growing remote patient monitoring and critical care markets. The company faces a competitive landscape with established players like Edwards Lifesciences and Masimo, but its unique algorithm-based solution offers a differentiated value proposition. Key near-term catalysts include FDA clearance for its next-generation software platform, expansion of commercial partnerships with integrated delivery networks, and potential Series B or later-stage financing to scale operations. If successful, Retia could capture a meaningful share of the $5B+ global cardiac output monitoring market. However, execution risks remain, including regulatory hurdles and competition from emerging AI-driven monitoring platforms. Overall, Retia Medical represents a compelling opportunity in non-invasive cardiovascular monitoring with a clear path to commercialization.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Argos Infinity Software Update70% success
• Q4 2026Commercial Partnership with a Major U.S. Hospital Network60% success
• Q1 2027Series B Funding Round ($15-25M)55% success